Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?

Guidelines on immunoprophylaxis for prevention of RSV infection recommend it in preterm babies born before 29 wGA; in babies affected by bronchopulmonary dysplasia or congenital heart defects; and in post-heart transplantation patients. On the contrary, immunoprophylaxis is not recommended in preter...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuccotti, Gianvincenzo, Fabiano, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347811/
https://www.ncbi.nlm.nih.gov/pubmed/28257653
http://dx.doi.org/10.1186/s13052-017-0341-4
_version_ 1782514115972956160
author Zuccotti, Gianvincenzo
Fabiano, Valentina
author_facet Zuccotti, Gianvincenzo
Fabiano, Valentina
author_sort Zuccotti, Gianvincenzo
collection PubMed
description Guidelines on immunoprophylaxis for prevention of RSV infection recommend it in preterm babies born before 29 wGA; in babies affected by bronchopulmonary dysplasia or congenital heart defects; and in post-heart transplantation patients. On the contrary, immunoprophylaxis is not recommended in preterm babies born between 29 and 35 wGA. We evaluated the impact of RSV-related healthcare expenditures in infants in the first 3 years of life in Italy, Lombardy Region. In light of the collected data and considering the cost of a complete palivizumab prophylaxis, extending it to babies 29–32 wGA, aged less than 6 months, appears to be a cost-effective strategy.
format Online
Article
Text
id pubmed-5347811
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53478112017-03-14 Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating? Zuccotti, Gianvincenzo Fabiano, Valentina Ital J Pediatr Letter to the Editor Guidelines on immunoprophylaxis for prevention of RSV infection recommend it in preterm babies born before 29 wGA; in babies affected by bronchopulmonary dysplasia or congenital heart defects; and in post-heart transplantation patients. On the contrary, immunoprophylaxis is not recommended in preterm babies born between 29 and 35 wGA. We evaluated the impact of RSV-related healthcare expenditures in infants in the first 3 years of life in Italy, Lombardy Region. In light of the collected data and considering the cost of a complete palivizumab prophylaxis, extending it to babies 29–32 wGA, aged less than 6 months, appears to be a cost-effective strategy. BioMed Central 2017-02-02 /pmc/articles/PMC5347811/ /pubmed/28257653 http://dx.doi.org/10.1186/s13052-017-0341-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Zuccotti, Gianvincenzo
Fabiano, Valentina
Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
title Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
title_full Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
title_fullStr Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
title_full_unstemmed Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
title_short Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
title_sort indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wga group: is there still room for debating?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347811/
https://www.ncbi.nlm.nih.gov/pubmed/28257653
http://dx.doi.org/10.1186/s13052-017-0341-4
work_keys_str_mv AT zuccottigianvincenzo indicationstorespiratorysyncytialvirusimmunoprophylaxisinthe2932wgagroupistherestillroomfordebating
AT fabianovalentina indicationstorespiratorysyncytialvirusimmunoprophylaxisinthe2932wgagroupistherestillroomfordebating

Ejemplares similares